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NUCLEAR TRANSLOCATION OF MET VIA INTERNET MECHANISM  
Abstract 
Mei-Kuang Chen, M.S. 
Advisory Professor: Mien-Chie Hung, Ph.D. 
 
MET is one of the receptor tyrosine kinases (RTKs) that are overexpressed in 
malignant cancer types, including breast cancer. While RTKs are traditionally known for 
their roles in signaling transduction from the cell surface, recent studies have provided 
evidence demonstrating that most of RTKs can translocate into nucleus to regulate cellular 
processes in response to both ligand and stress stimulation. Oxidative stress is a common 
stress in cancer cells due to alteration of metabolism, and constitutive oxidative stress 
related to reactive oxygen species (ROS) has been observed in breast cancer cells. Here, 
we show that hepatocyte growth factor (HGF) as well as hydrogen peroxide (H2O2) can 
induce nuclear translocation of full-length MET holoreceptor via a membrane-bound 
vesicle transport mechanism in breast cancer cells. Our findings provide a putative 
mechanism by which breast cancer cells adapt to oxidative stress.  
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Chapter 1 Introduction 
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1.1 Receptor Tyrosine Kinase and Cell Signaling 
Receptor tyrosine kinases (RTKs) are cell surface transmembrane receptors for growth 
factors, cytokines and hormones.  The first RTK was discovered in 1960s, and so far there 
are 58 known RTKs in human and are categorized into 20 subfamilies (Figure. 1) (Gschwind 
et al., 2004; Lemmon and Schlessinger, 2010; Robinson et al., 2000).   
 
Figure 1. Receptor Tyrosine Kinases Subfamilies.  The human receptor tyrosine 
kinases contain 20 subfamilies as listed on the top of the figure.   
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1.1.1 Ligand-induced RTK activation 
These RTKs have various ligand-binding domains in extracellular region, a single 
transmembrane domain, cytoplasmic domain and carboxy-terminal domain (C-term) next to 
the juxtamembrane regions (Lemmon and Schlessinger, 2010).  Generally, most of the 
activation of RTKs begins with ligand induced receptor oligomerization (Ullrich and 
Schlessinger, 1990).  After stimulation, the receptors were trans autophosphorylated 
(Favelyukis et al., 2001; Furdui et al., 2006; Honegger et al., 1989) and can dramatically 
increase its own kinase activity (Cobb et al., 1989; Furdui et al., 2006).  The main function 
of RTKs is catalyzing the transfer of γ-phosphate from adenosine-5’-triphosphate (ATP) to the 
target proteins on hydroxyl group of its tyrosine (Y) residues.  The downstream adaptor 
proteins commonly have a plasma membrane targeting site at N-terminal as well as Src 
homology 2 (SH2) or phosphotyrosine-binding domain (PTB) domain that recognizes 
phosphotyrosine on RTKs (Krauss, 2014; Lemmon and Schlessinger, 2010).  With the 
activated C-terminal domain, the RTK recruits adaptor proteins close to plasma membrane 
and induces signaling cascade through phosphorylating and activating the downstream 
proteins (Figure 2).  The type of downstream proteins recruited determines the signaling 
pathway activated by RTKs (Riedel et al., 1989).  Some RTKs are considered oncogenic and 
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also considered as therapeutic target because their high mutation rate in cancer.  These 
mutated RTK signaling promotes essential progresses in tumorigenesis such as cell 
proliferation, migration and survival (Feldser and Kern, 2001). 
 
 
Figure 2. Canonical Receptor Tyrosine Kinase Cell Signaling Cascade. Ligand 
binding stabilizes the RTK dimer and induces RTK trans- autophosphrylation. The adaptor 
proteins are recruited by phspho-RTKs and recognize the phosphor-tyrosine on the RTK, 
which activates the adaptor protein.  The activated adaptor protein will then further activate 
downstream signaling proteins and transduce the signaling into cell nucleus and regulate the 
cellular response to RTK signal. 
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1.1.2 Ligand-independent RTK activation 
The spatial distribution of RTK is the key step for signal transduction, and the receptors 
need lateral homophilic and heterophilic cis-interaction along with intercellular trans-
interaction to form the signaling foci (Bethani et al., 2010; Casaletto and McClatchey, 2012).  
Accumulating evidences indicate RTKs can also form dimers or oligomers without ligand and 
become active or form the complex primed for ligand-dependent activation (Chung et al., 2010; 
Clayton et al., 2007; Harding and Hancock, 2008; Himanen and Nikolov, 2003; Inder et al., 
2008; Szabo et al., 2010). 
1.1.2.1 RTK Alteration 
The RTK activation begins with receptor dimerization and auto-phosphorylation, 
besides ligand induction, the overexpression of receptor also increases the intensity of receptor 
leads to altered plasma membrane and receptor clustering to raise the potential for ligand-
independent dimerization and activation (Chung et al., 2010; Wei et al., 2005).  Also, the 
abnormal RTK structure can alter the receptor activation.  For example, an EGFR variant is 
reported to form activated dimer with only single ligand instead of the ligand dimer due to the 
structural difference in the extracellular domain (Alvarado et al., 2010).  Some mutations 
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occur in the RTK kinase domain and let the mutant much easier to be phosphorylated at critical 
tyrosine residues (Chen et al., 2007; Moriki et al., 2001). 
1.1.2.2 Redox Regulation on RTK signaling 
Previous studies have shown that reactive oxygen species (ROS), such as hydrogen 
peroxide (H2O2), participates in some physiological process, including cell growth, 
transformation, cell death and senescence (Finkel, 2003; Irani, 2000).  Moreover, previous 
studies also show that ROS also activate several RTKs (Martindale and Holbrook, 2002; 
Nishinaka and Yabe-Nishimura, 2001).  The oxidation agent, such as H2O2, can oxidize and 
to inhibit PTPs, which promote RTK signaling by prevent the prompt inactivation of RTK by 
PTPs (Chiarugi and Cirri, 2003; Chiarugi and Giannoni, 2005).  Further, it has been reported 
that H2O2 also trans-activate EGFR signaling through alteration of Src signaling (Zhuang and 
Schnellmann, 2004) and oxidized lipid component can leads to change and distribution of 
lipid cluster in local concentration to activate several RTKs including EGFR and PDGFR 
(Akiba et al., 2006; Negre-Salvayre et al., 2003). 
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1.2 C-MET (Hepatocyte growth factor receptor) 
MET, also known as hepatocyte growth factor/scatter factor (HGF/SF) receptor, is a 
proto-oncogenic RTK which plays crucial roles in cell proliferation and motility as well as in 
promoting cancer.  HGF/SF is a normal endogenous ligand for MET and is mainly produced 
by mesenchymal origin cells, while HGF acts as pleiotropic factor and cytokine to regulate 
cell proliferation, growth, mitosis and shape in different types of cells through either endocrine 
or paracrine mechanisms (Basilico et al., 2008; Bottaro et al., 1991; Cortner et al., 1995; 
Naldini et al., 1991; van der Voort et al., 2000).  First discovered in the 1980s, 170-kDa pro-
MET is N-linked glycosylated and this precursor is further cleaved to form a 45-kDa α subunit 
and a 150-kDa glycosylated β subunit, the two subunits are then joined by di-sulfite bonds to 
give mature MET (Chen et al., 2013; Cooper et al., 1984).  After HGF/SF stimulation, MET 
forms homodimer and trans-autophosphorylates each other at Y1230, Y1234 and Y1235 
residues, and phosphorylates Y1349 and Y1356 successively, then the specific phosphorylated 
residues provide docking sites for downstream messenger proteins including PI3K, Ras, STAT 
and Grb1 thus regulate cellular growth and survival (Fig. 3) (Ma et al., 2003; Organ and Tsao, 
2011; Ponzetto et al., 1994; Rodrigues and Park, 1994).  However, MET not only forms 
homodimers, but also transactivated by other surface molecules such as the v6 splice variant 
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of hyaluronan receptor CD44/intercellular adhesion molecule 1 (ICAM1), α6β4 integrin, G-
protein couple receptors (GPCRs) and other RTKs (Trusolino et al., 2010).  While dimerizing 
with these cell surface molecules, the downstream signaling were initiated through 
amplification of either MET activation or its binding molecules (Trusolino et al., 2010). 
 
 
Figure 3. Structure and downstream signaling of MET.  There are many different 
domains in MET, the pro-MET (left panel) will be cleavage in the SEMA domain to produce 
α and β subunits, these subunits are linked by disulfite bond to create mature MET (right 
panel). 
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Besides activation of MET signaling pathways, down regulation of MET signaling is 
essential for cellular regulation, and many mechanisms are involved in the negative regulation.  
The protein tyrosine phosphatase (PTPs) inactivate MET activity by dephosphorylates MET 
at either the kinase domain or the docking tyrosine sites (Machide et al., 2006; Sangwan et al., 
2008; Villa-Moruzzi et al., 1998).  While HGF induces MET phosphorylation at multiple 
activation site, it also promotes the phosphorylation on MET negative regulation sites such as 
serine 985 (S985) and Y1003 residues.  MET S985 is phosphorylated by protein kinase C 
(PKC) and leads to decreased tyrosine phosphorylation of MET, while the protein phosphatase 
2A (PP2A) can dephosphorylate S985 to retain MET activity (Gandino et al., 1994; 
Hashigasako et al., 2004).  On the other hand, E3 ubiquitin ligase casitas B-lineage 
lymphoma (c-CBL) is recruited by phosphorylated MET Y1003 and the MET-associated 
adaptor protein, Grb2 to promote receptor ubiquitination process and thus enhance MET 
internalization and degradation (Lefebvre et al., 2012; Petrelli et al., 2002).   
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1.3 MET Endosomal Trafficking — Endocytosis, Degradation and Recycling 
The MET signaling not only exist on cell surface but also on endosomes before receptors 
were degraded (Kermorgant et al., 2004; McPherson et al., 2001; Miaczynska et al., 2004).  
Further, endosomal MET signaling is required for maximizing downstream signaling 
activation and is highly related to MET-induced tumorigenesis (Barrow et al., 2014; Joffre et 
al., 2011).  Although the mechanisms of RTK, as well as MET, endocytosis, recycling and 
degradation are well-studied, little is known to the mechanism of RTKs nuclear trafficking.  
Receptor endocytosis affects the physiology of cells such as motility and cell fate by 
regulating receptor trafficking rate to control signal duration and subcellular location, and 
clathrin-mediated endocytosis (CME) is a major mechanism for down-regulating activated 
MET signaling (Fig. 4) (Barrow et al., 2014; Clague, 2011; Goh and Sorkin, 2013; Polo and 
Di Fiore, 2006).  The process of MET internalization begins with receptor ubiquitylation, 
and the process is controlled by a complex including c-Cbl, endophilins and CIN85 as well as 
cargo-specific adaptor proteins such as AP2 (McMahon and Boucrot, 2011; Petrelli et al., 
2002).  Endophilins regulates the formation of clathrin-coated vesicle through 
acyltransferase activity, which affects the phospholipids on cell membrane and leads to 
negative curvature and formation of endocytotic compartment from plasma membrane 
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(Schmidt et al., 1999).  Except clathrin, AP2 is the most abundant protein in the clathrin-
coated cargos, while AP2 is highly conservative and specifically act on plasma membrane 
(Robinson, 2004).  AP2 and the receptor specific cargo accessory adaptor proteins recruited 
to the vesicle will determine the fate of the vesicles.  The vesicles are then send to sorting 
endosomes, where it is determined to travel back to the plasma membrane (recycling) or to 
lysosomes (McMahon and Boucrot, 2011).  MET signaling is terminated when the 
ubiquitylated receptor in the vesicle is recognized by the ESCRT (endosomal sorting complex 
required for transport) and send to lysosomal degradation (Goh and Sorkin, 2013; Jeffers et 
al., 1997).  The endosomal trafficking for degradation is through early endosome to late 
endosome and lysosome, the pH value of between compartments is gradually decreased to pH 
5.0 in the lysosome for protein degradation (Goh and Sorkin, 2013; Yamashiro and Maxfield, 
1984). 
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 Figure 4. Endocytic trafficking of MET in response to ligand stimulation.  
MET undergoes clathrin mediated endocytosis after ligand-induced dimerization.  The 
internalized MET are transported to early endosome to determine whether recycling or 
degradation before send to late endosome and lysosome for lysosomal degradation. 
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1.4 Membrane Receptor in the Nucleus (MRIN) 
Various RTKs have been reported to be shuttled from plasma membrane into cell nucleus, 
including EGFR, ERRB2, VEGFR, FGFR, MET and IGF1R (Carpenter and Liao, 2013; Feng 
et al., 1999; Kermorgant and Parker, 2008; Sehat et al., 2010; Wang et al., 2012), and had been 
reported to have important physiological and pathological roles in nucleus.  These nuclear 
RTKs are now termed membrane receptors in the nucleus (MRINs) (Wang and Hung, 2009).   
The nuclear function of MRINs is most studied in epidermal growth factor receptor 
(EGFR) and fibroblast growth factor receptor (FGFR), that includes transcriptional regulation, 
DNA replication and DNA repair regulation and even RNA metabolism (Planque, 2006; Wang 
et al., 2010b).   
 
1.4.1  Nuclear EGFR 
Every member in EGFR family, including EGFR, ErbB2, ErbB3, and ErbB4 has been 
reported to translocate into nucleus in different types of cells and human cancers, and nuclear 
EGFR has correlation with poor prognosis for many types of cancer (Carpenter and Liao, 2013; 
Hadzisejdic et al., 2010; Hoshino et al., 2007; Traynor et al., 2013; Wang and Hung, 2009; 
Wang et al., 2010b).  EGFR nuclear translocation can be triggered by ligand stimulation and 
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cellular stress, such as ultraviolet and ionizing radiation (Chen and Nirodi, 2007; Dittmann et 
al., 2005; Lin et al., 2001; Oksvold et al., 2004; Xu et al., 2009).   
Since both ligand and stress can stimulate EGFR nuclear translocation, the functions of 
nuclear EGFR cover many aspects from cell proliferation to DNA repair.  EGFR can act as 
an EGF-dependent transcriptional cofactor by regulating target gene expression through 
binding with RNA helicase A and recognize specific AT-rich sequence in the promoter region 
of those target genes and promote cell proliferation (Huo et al., 2010; Lin et al., 2001; Lo and 
Hung, 2006).  On the other hand, EGFR can also regulate gene expression through interact 
with other co-regulators, for example, signal transducers and activators of transcription protein 
3 and 5 (STAT3 and STAT5), transmembrane mucin 1 (MUC1) and Epstein-barr virus-
encoded latent membrane protein 1 (LMP1) (Bitler et al., 2010; Hung et al., 2008; Huo et al., 
2010; Jaganathan et al., 2011; Tao et al., 2005).  When cells encountered cellular stress like 
radiation, oxidative stress or DNA-damaging reagents such as cisplatin, EGFR can translocate 
into nucleus in a ligand-independent manner and activate DNA repair process through 
phosphorylate its substrates such as DNA protein kinase (DNA-PK), Ku proteins and PCNA 
(Bandyopadhyay et al., 1998; Chen and Nirodi, 2007; Friedmann et al., 2006; Javvadi et al., 
2012; Liccardi et al., 2011; Park et al., 2010; Yu et al., 2013).   
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1.4.2  Nuclear FGFR-1 
It has been reported that FGFR-1 accumulates in the nucleus and plays a role as 
transcriptional regulator when aided by FGF-2, ribosomal S6 kinase isoform 1 (RSK1) and 
CREB-binding protein (CBP) (Bryant and Stow, 2005; Dunham-Ems et al., 2009; Johnston et 
al., 1995; Lee et al., 2013; Stachowiak et al., 1997).  FGFR1 has physical interaction with 
RSK1, a CBP and histone phosphorylation regulator, and regulates RSK1 transcription 
activities (Hu et al., 2004).  By recruiting the RNA polymerase II and histone acetylation on 
the promoters, FGFR1 up-regulate the target genes through binding with CBP (Peng et al., 
2002; Stachowiak et al., 2003).   
Moreover, the nuclear FGFR1 also promotes cancer invasion in different types of cancer 
through regulating gene expression (Chioni and Grose, 2012; Coleman et al., 2014).  More 
and more genes are identified as targets of nuclear FGFR1, e.g., the genes of neurofilament-
L, neuron-specific enolase microtubule associated protein-2 (MAP2), c-jun and cyclin D1 
(Reilly and Maher, 2001; Stachowiak et al., 2003).  By regulating the expression of target 
gene, nuclear FGFR1 is involved in cell growth and differentiation.  The transactivation 
function of FGFR1 is independent from the surface FGFR1 signaling, suggesting the distinct 
function of nuclear RTK from that on plasma membrane.     
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1.4.3  Nuclear MET 
MET is also a member of MRINs, the internalization of MET starts from clathrin and 
dynamin-dependent endocytosis as many other MRINs such as EGFR and ErbB-2 (Goh and 
Sorkin, 2013; Hammond et al., 2001; Hoffmann et al., 2006; Kermorgant et al., 2003; 
Kermorgant et al., 2004; Wang et al., 2012).  However, the function of nuclear MET is not 
yet well studied.  So far, Matteucci et al. demonstrated MET holo-receptor localization in 
cell nucleus is independent from HGF stimulation in MDA-MB-231 cells (Matteucci et al., 
2009) and several groups have demonstrated that 60-kDa MET C-terminal fragment (CTF) 
form has to locate in nucleus to initiate calcium signaling and have suggested that the 
juxtamembrane domain preceding the tyrosine kinase domain seems indispensable for nuclear 
localization and transactivation activity (Gomes et al., 2008; Matteucci et al., 2009; Pozner-
Moulis et al., 2006).  Meanwhile, evidences reveal that nuclear localized MET is involved in 
non-canonical signal transduction such as accelerate STAT3 nuclear accumulation 
(Kermorgant and Parker, 2008).  However, whether the MET holo-receptor translocates from 
plasma membrane into nucleus in response to stimulation and what is the nuclear trafficking 
mechanism utilized by MET still remains unclear. 
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1.5 Nuclear Trafficking mechanism of MRIN 
It is important to investigate the intercellular trafficking of RTKs to clarify how spatial 
distribution affect endosomal RTKs signaling and further identify the potential inhibitors.  
There are several hypotheses regarding how membrane receptor tyrosine kinase are 
transported into cell nucleus.  As illustrated in Figure 5, there are two main trafficking 
pathways regarding how MRINs translocate into nucleus: (I) Protease-dependent route and 
(II) holoreceptor route (II) Protease-independent route — the holo-receptor tyrosine kinase 
translocate into nucleus through clathrin mediated endocytic or similar mechanisms, then 
travel with trafficking vesicle through membrane bound mechanism (Carpenter and Liao, 
2013; Du et al., 2013; Song et al., 2013; Wang et al., 2012; Wang et al., 2010c).   
 
Figure 5. RTK nuclear transportation pathways in mammalian cells.  There are 
two nuclear transportation pathways for RTKs, the protease-dependent route (left panel) and 
the holo-receptor route (right panel). 
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1.5.1 Protease-dependent RTK nuclear transportation mechanism 
Generally, in the protease-dependent RTK trafficking mechanism, sequential proteolytic 
cleavage happened to the receptor after ligand binding.  First, the receptor undergoes 
protease cleavage and release the extracellular domain, then the further cleavage at RTK 
transmembrane domain leads to production of intracellular domain (ICD), and then the ICD 
is released into cell cytosol to translocate into nucleus directly (Fortini, 2002; Fortini, 2009). 
The mechanisms of ICD fragment varies in response to different stimulation (Carpenter 
and Liao, 2013), including secretase-dependent, caspase-dependent, translation-dependent, 
splicing-dependent and granzyme-dependent pathways.  The most studied mechanism is the 
secretase-dependent ICD formation: the ligand-bound RTKs are first cleavage by α-secretase 
to release the extracellular domain, then the second cleavage is performed by γ-secretase at 
the juxtamembrane domain to release ICD from transmembrane domain.   Currently, several 
receptors are reported to follow this nuclear trafficking route, including ErbB4, ephrin 
receptors, IGF1R, insulin receptor and VEGFR1 (Georgakopoulos et al., 2006; Ni et al., 2003). 
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1.5.2 Protease-independent nuclear transportation mechanism 
More and more full-length RTKs has been reported to translocate in nucleus, and these 
RTKs are shown to appear in nucleoplasm rather than nuclear envelope (Carpenter and Liao, 
2013).  The RTKs are known to translocate from nuclear envelope into nucleus through the 
help of importin complex.  Importin β, which is directly associates with nucleoporins, is a 
protein which can interact with the nuclear localization signals (NLSs) on the RTKs and 
transport RTKs into nucleus (Reilly and Maher, 2001; Walther et al., 2001; Wang et al., 2010c). 
When the cell surface molecules be internalized into cytosol by endocytosis, the first 
organelle those molecules transported to is Golgi apparatus (Bos et al., 1995; Duncan and 
Kornfeld, 1988; Farquhar, 1985; Roth et al., 1985).  The retrograde trafficking is different 
from endocytosis part, the retrograde sorting begins with cargo molecules targeting to 
endosomes from Golgi apparatus or plasma membrane.  Illustrated in Figure 6, the cargo 
vesicles are retrograde transported to trans-Golgi network (TGN), Golgi membrane or ER 
(Bonifacino and Rojas, 2006; Johannes and Popoff, 2008). 
Clathrin-binding proteins are not only essential for endocytosis, but also required for 
cargo transportation from early endosome to TGN (Hinners and Tooze, 2003; Shi et al., 2009).  
After transported to Golgi and TGN, the retrograde membrane vesicle transportation 
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mechanism includes the trafficking from Golgi body to ER where coat protein complex I 
(COPI)-coated vesicle are an essential carrier which carries MRINs between Golgi stacks and 
also carries MRINs from Golgi to ER (Pellett et al., 2013; Spang, 2013; Wang et al., 2010a).  
In addition, after MRINs reached ER, the beta subunit of Sec61 translocon (Sec61β) is 
indispensable for MRINs to be transported from ER into cell nucleus (Greenfield and High, 
1999; Wang et al., 2010c).  There are at least two typical trafficking mechanisms for RTK 
holoreceptor transportation from Golgi apparatus into nucleus: (I) the INTERNET mechanism, 
and (II) the INFS mechanism (Wang et al., 2012).  However, the nuclear trafficking 
mechanism is not well-studied in all reported MRINs. 
1.5.2.1 INFS nuclear transportation mechanism 
Some RTKs, for example FGFR1 and FGFR2, translocate into nucleus through INFS 
(integrative nuclear FGFR-1 signaling) mechanism.  Briefly, the RTKs are internalized and 
transported to Golgi apparatus, however, these RTKs are released from pre-Golgi or 
endoplasmic reticulum (ER) into cytosol and transported to the nucleus by indirectly 
interaction with importin β (Dunham-Ems et al., 2009; Reilly and Maher, 2001; Stachowiak 
et al., 2003; Stachowiak et al., 2007). 
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1.5.2.2 INTERNET nuclear transportation mechanism 
For the INTERNET (integral trafficking from the ER to the nuclear envelope transport) 
mechanism, the RTKs, such as EGFR, are internalized through endocytosis and transported to 
the nucleus through Golgi apparatus to ER retrograde membrane-vesicle transportation route 
and depend on the inner nuclear membrane (INM) to translocate into nucleus.      
After reaching ER, these RTKs are further translocate in a Sec61 translocon complex-
dependent manner to the inner nuclear membrane (INM) through the nuclear pore complexes 
(NPCs) with the assistance of importin β (Wang et al., 2010c).  In this study, we hypothesized 
that MET holo-receptor responses to cellular stress, such as oxidative stress, and transports 
into nucleus through the COPI and Sec61β-mediated nuclear trafficking pathway. 
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Figure 6. RTK retrograde nuclear transportation mechanisms.  After surface 
molecules internalized by endocytosis, the cargo are sent to endosome for sorting.  The 
molecules are then transported with the aid of different adaptor proteins to Golgi apparatus, 
followed by transported to ER through COPI-coated vesicles.  The molecules are then 
translocate into nucleus through NPCs by either INTERNET or INFS mechanism. 
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1.6 MET Overexpression Indicates Poor Prognosis in Breast Cancer Patients 
According to data revealed from the World Health Organization (WHO) in 2008, breast 
cancer is the most common cancer in women and also the most common cancer that leads to 
death among women worldwide (Jemal et al., 2011).  And the data provided by Surveillance, 
Epidemiology and End Results (SEER) Cancer Statistics Review shows that in 2014, it is 
estimated that the new cases will be 232,670 people and stands for 14% of all new cancer 
cases (Howlader N, 2014). 
So far, there are two systems in grouping breast cancer subtypes.  One is based on the 
gene expression, the other is based on the expression level of hormone receptors.  There are 
at least five subtypes in breast cancer carcinoma according to their gene expression pattern, 
denoted as luminal A and B, basal-like, HER2 enriched and normal-like (Cadoo, 2013).  
Another way to group the breast cancer cell is based on their expression level of three 
important hormone receptors, estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor (HER2).  These receptors serve as biomarkers for breast 
cancer because their great influence on tumor growth and metastasis.  Clinically, breast 
cancer cells can be grouped into ER/PR positive, ERBB2 (HER2) overexpression and the 
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breast cancer cell which lack of ER, PR, overexpressed ERBB2 is called triple negative breast 
cancer (TNBC) (Riaz et al., 2013).  
MET overexpression is known to be an indicator of poor prognosis in all subtypes of 
breast cancer and the MET signaling also promotes drug resistance and recurrence (Eterno et 
al., 2013; Inanc et al., 2014; Raghav et al., 2012; Shattuck et al., 2008; Zagouri et al., 2013).  
Indeed, high MET protein expression is also found in many breast cancer cell lines, especially 
in TNBC cells (Fig. 7), which suggesting that MET expression may potentially be correlated 
to the malignancy of cancer cells.   
 
Figure 7. MET Protein Expression in Breast Cancer Cell Lines.  The MET protein 
expression level is generally higher in TNBC cell lines.  The subtypes were grouped 
according to ER, PGR, ERBB2 protein expression level reported by Riaz et al. (Riaz et al., 
2013). 
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1.7 Specific Aims 
Accumulating evidences show that RTK signaling and cellular function depend on the 
sub-cellular location.  In particular, nuclear localized RTK has been reported to participate 
in numerous tumorigenesis pathways.  The sub-cellular transportation of RTKs can be 
induced by both ligand and cellular stress, while cells are normally more sensitive to stress-
induced transportation.  Given that MET is an important RTK in various cancer types, it is 
important to find out the potential endosomal signaling and nuclear function of MET. 
Among different cellular stress, reactive oxygen species (ROS) is one of the common 
stresses occur in tumor cells, either produced from metabolism or as a product while response 
to anti-cancer drug.  This study mainly focuses on the trafficking mechanism of ligand and 
ROS induced MET nuclear transportation, and aimed on providing more knowledge about 
RTK transportation under ROS stress.   
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Chapter 2  Materials and Methods 
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2.1 Experimental reagents   
The antibodies used in this study are as follows: anti-MET antibodies (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA; GeneTex, Inc., Irvine, CA, USA), anti-lamin B 
antibodies, anti-calregulin antibodies, anti-COPI antibodies (Santa Cruz Biotechnology Inc.), 
anti-Sec61β antibodies (GeneTex, Inc.).  Hepatocyte growth factor (HGF) human 
recombinant was purchased from BioVision Inc. (San Francisco, CA, USA), hydrogen 
peroxide (H2O2) and brefeldin A were purchased from Sigma-Aldrich (St Louis, MO, USA). 
Brefeldin A was dissolved in methanol to generate 5 μg/mL stock solution. 
 
2.2 Cell culture and treatments   
Breast cancer cells lines were originally obtained from ATCC. MDA-MB-231, BT549, 
Hs578T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12 
supplied with 10% fetal bovine serum and 100 U/mL penicillin and 100 μg/mL streptomycin.  
MCF-10A and MCF-12A cells were maintained in DMEM/F12 medium supplied with 5.2% 
horse serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 μg/mL insulin, 20 ng/mL 
EGF, 100 ng/mL cholera enterotoxin, 0.5 μg/mL hydrocortisone and 1.05 mM calcium 
chloride.  Cells were treated with 100 ng/mL HGF or 10 μM H2O2 within culture medium 
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and incubated in 37℃, water-saturate incubator supplied with 5% CO2.  For Golgi body 
inhibition, cells were pre-treated with 5 μg/mL BFA before other treatments. 
 
2.3 Whole cell extract preparation 
Cells were cultured until reaching 90% confluent before subjected to whole cell 
extraction.  The culture medium were removed and the cells were washed with ice-cold PBS 
twice before harvested by scrapping.  The cells were then pelleted by centrifuge 1800хg at 4 
℃ for 5 min and re-  (150 mM NaCl, 1 mM EDTA, 20 
mM Tris pH 8.0, 0.5% Nonidet P-40), then were sonicated (Sonics Vibra-Cell, amplitude 30, 
10 sec; Sonics & Materials, Newtown, CT).  The supernatant were then collected as whole 
cell extract after centrifugation at maximum speed. 
 
2.4 Cellular fractionation   
To investigate the subcellular location of MET, we performed cell fractionation to 
separate cell nuclear from the rest parts of cells.  The nuclear fraction and non-nuclear 
fraction of cells were prepared as described (Du et al., 2013).  Briefly, cells were harvest at 
90% confluent and subjected to lysed in nori lysis buffer (20 mM HEPES, pH 7.0, 10 mM 
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KCl, 2 mM MgCl2, 0.5% Nonidet P-40) on ice for 1 h.  The cells were then homogenized by 
Dounce homogenizer. After centrifuged, the supernatant were collected as non-nuclear 
fraction.  The pelleted nuclei were washed with lysis buffer twice followed by re-suspended 
and incubated for 10 min on ice in NETN buffer before sonication (Sonics Vibra-Cell, 
amplitude 30, 10 sec).  The extract was then centrifuged and the supernatant were collected 
as nuclear fraction. 
 
2.5 Subcellular protein extraction 
The extraction of cytosolic, organelle membrane and nuclear protein extraction was 
performed with ProteoExtract®  Subcellular Proteome Extraction Kit (Calbiochem®  Merck 
Millipore, MA, USA) as described (Wang et al., 2012).  Generally, the subcellular proteins 
were prepared following the manufacturer’s instructions.  Mitochondria, as well as cell 
membrane, were removed from organelle membrane-enrich fraction by centrifugation at 
20,000 x g for 30 min (Borradaile et al., 2006; Nigam et al., 1994). 
 
 30 
2.6 RNA interference   
To establish stable COPI or Sec61β knock-down clones, the plasmid were transfected 
into MDA-MB-231 cells with lentivirus infection.  The stable clones were cultured with 1% 
puromycin-containing DMEM/F12 selective medium.  The shRNA expression vectors with 
pLKO.1 backbone were purchased from Sigma-Aldrich, the COPI knock-down stable clones 
were kindly provided by Dr. Yi Du and the Sec61β siRNA targets sequence NM_006808 were 
purchased from GE Healthcare.  The scramble shRNA (Addgene plasmid 1864) is used as 
non-targeting shRNA control (Sarbassov et al., 2005).  The same procedures were used for 
generate stable MET knock-down clones in MDA-MB-231 cells.  The GIPZ lentiviral 
shRNA were purchased from Thermo Fisher Scientific (Pittsburgh PA, USA), the shMET A 
and B both target sequence of MET ORF while shMET C targets the sequence of MET 3’-
UTR.  The RNAi sequence is listed in Table 1 and 2. 
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Table 1. MET shRNA Clone ID 
 
Table 2. Sec61β siRNA Probe ID 
# Final # NCBI Probe ID Gene Accession number Species 
1 1 12262229 Sec61B NM_006808 human 
2 2 12262230 Sec61B NM_006808 human 
3 3 12262231 Sec61B NM_006808 human 
4 4 12262232 Sec61B NM_006808 human 
 
  
# 
Final 
# 
Oligo ID/clone 
ID 
Gene Accession number Species Mature anti-sense Sequence 
1  V2LHS_76542 HGFR/MET 
NM_000245, 
NM_031517 
human TATTACAGGATCCACATAG 
2  V2LHS_76541 HGFR/MET NM_000245 human ATAGATGTTAAGAGGACTTCGC 
3 A V3LHS_381509 HGFR/MET NM_000245 human TAGAATGACATTCTGGATGGGT 
4  V3LHS_381505 HGFR/MET NM_000245 human TTTCTTGCCATCATTGTCCAA 
5 B V3LHS_381508 HGFR/MET 
NM_000245, 
NM_001127500 
human TAAACACTTCCTTCTTTGT 
6 C V3LHS_646098 
HGFR/MET 
(3' UTR) 
NM_000245, 
NM_001127500 
human TTAATTGCATGATTTATCA 
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2.7 Western blotting   
The Western blotting analysis was performed as described to detect the molecular 
weight of specific protein and the level of protein expression (Chen et al., 2011).  20 µg 
protein samples were boiled in protein sample buffer (12 mM Tris, pH 6.8, 0.4% SDS, 2% 
glycerol, 1% β-mercaptoethanol, 0.05% bromophenol blue) for 15 min before separated by 
8%/12% SDS (sodium dodecyl sulfate–polyacrylamide) gel electrophoresis.  Then the 
proteins were transferred onto Hybond-P polyvinylidene difluoride (PVDF) membranes under 
4℃.  Non-specific binding sites were blocked with 5% slim milk/TBST buffer (137 mM 
NaCl, 2.7 mM KCl, 25 mM Tris, 0.05% Tween-20, pH 7.4).  Primary antibody were 
hybridized under 4℃  shaking overnight and followed by HRP-conjugated secondary 
antibody hybridization.  To detect the antibody:antigen complexes, the blots were developed 
using enhanced chemiluminescence (ECL) kit (Biorad Inc., Hercules, CA, USA) according to 
the manufacturer's instructions.  The specificity of MET antibody was tested by comparing 
the signal level between MET shRNAs knock-down and MET non-targeting shRNA (shCtrl) 
MDA-MB-231 whole cell extract (Table1, Fig. 8). 
 33 
 
Figure 8. The specificity of MET antibody in Western blotting.  20 µg whole cell 
extract from MDA-MB-231 cells stable transfected with indicated shRNA were used for 
Western blotting.  The α-tubulin is used as loading control. 
 
 
2.8 Confocal microscopy   
The sample for confocal microscopy is prepared as described previously (Wang et al., 
2010a). In brief, cells were seeded on chamber slides at least 18 h before treatment.  After 
treatment, the cells were then washed with phosphate buffered saline (PBS) and fixed and 
stained with antibodies described below.  The cells were stained with primary antibodies 
followed by FITC or Texas Red-conjugated secondary antibody hybridization.  DNA were 
counterstained with DAPI-containing mounting solution (Vector Laboratories Inc., 
Burlingame, CA, USA). The samples were then imaged with Zeiss LSM 710 laser microscope. 
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2.9 Cell viability assay — MTT assay 
For cell viability assay, 1000 MDA-MB-231 cells were plated in 96-well flat bottom 
plates 24 h before exposed to doxorubicin for 72 h.  Then the MTT solution were added to 
each well at the final concentration of 1 mg/mL and incubated for 1 h.  After incubation, the 
MTT solution were removed and the formazan crystals were dissolved in 0.1 mL DMSO.  
The absorbance at 590 nm was determined with BioTech plate reader and the reference 
absorbance is 620 nm.  Each condition were triplicated and the viability is determined by 
calculating the percentage of O.D. 590 nm of each treatment to the control group. 
 
2.10 Statistical analysis   
The percentage of MET-containing cell nuclei was calculated based on the 
immunofluorescence images obtained by confocal microscopy.  For each experiment, at least 
50 cell nucleus were counted to be the denominator, the number of nucleus which contain 
MET signal is counted to be the numerator.  For Western blotting analysis, each experiment 
were repeated at least three times independently, the signal intensity is quantified by ImageJ 
(http://rsbweb.nih.gov/ij/index.html) (Schneider et al., 2012).   
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Chapter 3  
Results and Analysis 
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3.1 Nuclear translocation of MET 
3.1.1 Ligand induced MET nuclear transportation 
Previous studies have demonstrated that many RTKs translocate into nucleus in 
response to both ligand and cellular stress (Carpenter and Liao, 2013; Goh and Sorkin, 2013; 
Song et al., 2013).  To determine the subcellular location of MET after HGF treatment, we 
performed both cellular fractionation followed by Western blotting (Fig. 9).  Although it has 
been reported that full-length MET does not translocate to the nucleus upon HGF stimulation 
(200 ng/ml for 30 min) in MDA-MB-231 cells (Matteucci et al., 2009) , we found that 
prolonged HGF treatment (100 ng/mL for 1-6 hours) increased the protein levels of nuclear 
MET holoreceptor in both MDA-MB-231 and BT549 cells (Fig. 9).  
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(B)                                                                                   
 
 
 
Figure 9. Full-length MET nuclear localization after ligand treatment.  A, MDA-
MB-231 B, BT-549 cells at 90% confluence were treated with HGF for time indicated before 
harvested for cell fractionation.  20 μg proteins of each sample were used for Western 
blotting. C, Quantitation of MET protein level (folds) compare to untreated (0 h) group in 
non-nuclear and nuclear fractions.  The red dash line indicates 1 fold.  * p <0.05, ** 
p<0.005, n.s., non-significant difference. 
(A) 
(C) 
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3.1.2 ROS-induced MET nuclear translocation in breast cancer cells 
3.1.2.1 H2O2-induced MET transactivation 
As mentioned in Chapter 1.1.2.2, ROS can transactivate many RTKs.  In this study, 
H2O2 was used to generate ROS stress.  To verify if ROS can activate MET, the 
phosphorylation of MET Y1234/Y1235 were detected by Western blotting.  As shown in 
Figure 10, p-Y1234/1235 can be detected in cells after treated with 10 µM H2O2 30 min, and 
this phosphorylation can be blocked by crizotinib, a clinical used MET inhibitor. 
 
 
 
Figure 10. H2O2 induced MET activation can be blocked by crizotinib.  MDA-MB-
231 and BT-549 cells were treated with crizotinib at dose indicated for 24 h, followed by 30 
min 10 µM H2O2 treatment.  The cells were then harvested, and A, the phosphorylated MET 
Y1234/Y1235 residues  B, total MET protein level in whole cell extracts were detected by 
Western blotting.  C, α-tublin were used as loading control in Western blotting analysis. 
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In addition to HGF treatment, ROS also induces MET nuclear transportation in breast 
cancer cells.  In this study, MDA-MB-231 and BT-549 cells were treated with various 
concentrations of H2O2 for different times before harvested for cellular fractionation and 
Western blotting.  As shown in Figure 11, H2O2 treatment increased the levels of nuclear 
MET holoreceptor (145-kDa) in a dose-dependent manner.  The data indicated that a 30-min 
treatment of 10 μM H2O2 was sufficient to induce MET nuclear translocation in both cell 
lines.  Although treatment of 20 μM H2O2 induced MET translocation more substantially, 
we chose the 10 μM concentration for the time course study to avoid potential ROS-induced 
cell death.  
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(A)                                   (B) 
                                       
(C) 
 
 
Figure 11. H2O2-induced MET nuclear translocation is dose-dependent.   A, 
MDA-MB-231 B, BT-549 cells at 90% confluence were treated with H2O2 at dose indicated 
for 30 min before harvested for cell fractionation.  20 μg proteins of each sample were used 
for Western blotting. C, Quantitation of MET protein level (folds) compare to untreated (0 
µM) group in non-nuclear and nuclear fractions.  The red dash line indicates 1 fold.  * p 
<0.05, ** p<0.005, n.s., non-significant difference. 
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In order to figure out a proper condition for investigating the MET nuclear trafficking 
mechanism, the MET subcellular location is also detected in different time after H2O2 
treatment.  In both cell lines, nuclear accumulation of MET can be detected from 30 min to 
2 h following H2O2 treatment (Fig. 12).   
 
    
   
 
(A) (B) 
(C) 
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Figure 12. H2O2-induced MET nuclear translocation is time-dependent.  A, MDA-
MB-231  B, BT-549 cells at 90% confluence were treated with 10 µM H2O2 for indicated 
time before harvested for cell fractionation.  20 μg proteins of each sample were used for 
Western blotting.  C, Quantitation of MET protein level (folds) compare to untreated (0 h) 
group in non-nuclear and nuclear fractions.  The red dash line indicates 1 fold.  * p <0.05, 
** p<0.005, n.s., non-significant difference. 
 
 
To minimize the effect on cellular response to H2O2, a 30-min 10 μM H2O2 treatment 
was used in all subsequent experiments to investigate the trafficking mechanism of MET. 
H2O2-induced MET nuclear translocation was also validated in various breast cancer cell lines 
(Fig. 13) in which the level of nuclear MET holoreceptor was higher in H2O2-treated than in 
non-treated cells.  Interestingly, MET holoreceptor was the predominant contrary observed 
in the nucleus upon H2O2 treatment in several cell lines tested (Fig. 13).  
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Figure 13. MET nuclear translocation after H2O2 treatment.  Cells were treated 
with 10 μM H2O2 for 30 min before harvested for fractionation and Western blotting.  The 
MET expression level were calculated by comparing the MET signal intensity with the loading 
control (calregulin for non-nuclear fraction and lamin B for nuclear fraction).  The fold is 
calculated by the expression level of H2O2 treated group (H2O2 +) to untreated group (H2O2 
-). 
To further validate the nuclear translocated MET, immunostaining of MET was 
performed in both MDA-MB-231 and BT-549 cells for analysis by confocal microscopy.  As 
shown in Figure 14, MET was mainly found in the cytosol of both cell lines under normal 
culture condition (control), but aggregated near the nucleus after either HGF or H2O2 treatment.  
Through counting the number of nuclear MET-containing nuclei, we observed that the 
percentage of MDA-MB-231 cells with MET nuclear localization following H2O2 treatment 
increased about 2-fold compared with control and HGF-treated cells (Fig. 14 B).  The 
increase in HGF-induced nuclear MET was more substantial in BT-549 than in MDA-MB-
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231 cells (Fig. 14 B).  MET nuclear location was further verified by three-dimensional 
confocal microscope z-stack imaging (Fig. 15).  These results indicate that oxidative stress 
elicits stronger nuclear translocation of MET than ligand stimulation. 
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Figure 14 (A) 
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Figure 14 (B) 
 
Figure 14. MET subcellular location after HGF or H2O2 treatment.  A, Cells were 
treated with 100 ng/mL HGF for 2 h or H2O2 for 30 min and subjected to immunostaining 
with anti-MET (green fluorescence, Santa Cruz) and DAPI.  B, The percentage of MET-
containing cell nuclei in microcopy images.  The nucleus were indicated by DAPI, and at 
least 50 nuclei were counted in each group. 
 
 
 47 
Figure 15 (A) 
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Figure 15 (B) 
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Figure 15 (C) 
 
Figure 15. Z-stack confocal imaging of MET in MDA-MB-231 cells.  The cells were 
treated with A, untreated group B, 100 ng/mL HGF for 2 h and C, 10 µM H2O2 for 30 min 
before fixed and subjected to confocal microscopy.  The interval between slices is 0.30 µm. 
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3.2 MET Internalization from Plasma Membrane to Golgi Apparatus 
Based on the detection of the MET holoreceptor in nucleus, we speculated that MET 
nuclear trafficking might also follow the membrane-bound trafficking mechanism of EGFR. 
EGFR nuclear translocation begins with receptor endocytosis and microtubule dependent 
cargo transportation to Golgi apparatus (Du et al., 2013). 
3.2.1 MET internalization is microtubule-dependent. 
Because membrane-bound cargo transport requires microtubules, we asked whether 
disrupting microtubule assembly also affects MET nuclear transport.  Nocodazole is an anti-
mitotic drug, and it is known to inhibit microtubule polymerization through binding with 
tubulin (Xu et al., 2002).  Western blotting data showed that H2O2-induced MET nuclear 
translocation was reduced in cells pre-treated with nocodazole (Fig. 16), indicating 
microtubule is crucial to MET nuclear translocation.  
 
Figure 16. Nocodazole inhibits H2O2-induced MET nuclear translocation.  MDA-
MB-231 cells were treated with nocodazole 30 min before 10 μM H2O2 30 min treatment. 
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In the cellular cargo trafficking mechanism, dynein and kinesin are two important motor 
proteins which carry the cargo vesicle along the microtubule (Berg JM, 2002).  Moreover, 
dynein has been reported to affect EGFR nuclear transportation (Du et al., 2013), raising the 
possibility that dynein also involved in MET nuclear transportation.  However, MET is 
widely spread in the cytosol of MDA-MB-231 and BT-549 cell, and that leads to the 
difficulties in investigating the trafficking cross the cytosol by confocal imaging. 
 
3.2.2 MET nuclear trafficking mechanism is Golgi apparatus dependent. 
As demonstrated by Du et al., functional Golgi apparatus is essential in EGFR nuclear 
transportation in transfer the receptor from endocytic vesicles to ER (Du et al., 2013).  To 
validate if Golgi apparatus is also important in MET transportation, the brefeldin A (BFA) is 
introduced to disrupt normal Golgi apparatus function by jeopardizing its structure.  In this 
study, MDA-MB-231 cells were treated with BFA for 30 min prior to H2O2 treatment.  
Results from Western blot analysis showed that BFA treatment inhibited MET holoreceptor 
nuclear translocation (Fig.17), suggesting that MET holoreceptor translocates to the nucleus 
via a retrograde mechanism through the Golgi apparatus. 
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Figure 17. BFA blocks H2O2-induced MET nuclear transportation.  MDA-MB-
231 cells were pretreated with 5 μM BFA for 30 min prior to H2O2 treatment (10 µM) for 30 
min before cellular fractionation. 
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3.3 COPI and Sec61-mediated Retrograde Transportation of MET 
3.3.1 COPI-mediated MET retrograde transportation 
To test MET membrane-bound nuclear retrograde trafficking mechanism between the 
Golgi apparatus and ER, we knocked-down the COPI in MDA-MB-231 cell by shRNA to 
diminish vesicle trafficking from Golgi to ER.  Of the five COPI knockdown stable clones 
generated, two clones showed at least 50% inhibition of COPI protein expression as evaluated 
by Western blot analysis (Fig. 18). 
 
 
 
Figure 18. COPI knockdown efficiency in MDA-MB-231 cells.  The shRNA were 
stable transfected to MDA-MB-231 cells through retrovirus infection.  The transfectants 
were then selected with 1 μg/mL puromycin for 2 weeks to get stable clones. 
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As shown in Figure 19 A, the Western blotting data shows that knocking down COPI 
significantly decreased H2O2-induced MET nuclear translocation compared with scrambled 
control (shCtrl).  Meanwhile, similar phenomenon was also observed with 100 ng/mL HGF 
treatment (Fig. 19 B).  These data suggest COPI-mediated vesicle retrograde transportation 
mechanism is crucial to MET nuclear transportation. 
(A) 
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(B) 
 
 
 
Figure 19. Knock-down COPI diminishes MET nuclear translocation.  MDA-MB-
231 shCOPI stable clones were treated with A, H2O2 and B, HGF before fractionation, and 
isolated fractions were subjected to Western blot analysis with the indicated antibodies. 
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The immunofluorescent images also showed less MET-containing cell population after 
ligand and H2O2 treatment in COPI knocked-down cells than in control cells (Fig.22).  
Together, these results indicate that COPI plays an important role in MET nuclear trafficking 
and support our hypothesis that MET holorecpetor retrograde transports from Golgi to ER 
through a COPI-mediated vesicle trafficking mechanism. 
 
3.3.2 Sec61-mediated MET nuclear transportation 
MET is also speculated to translocate into nucleus through ER, which would require the 
Sec61 translocon complex.  According to previous studies, Sec61β is reported to be involved 
in membrane-bound nuclear transport of many RTKs (Wang et al., 2010c).  Here we used 
shRNA to knockdown Sec61β in MDA-MB-231 cells.  Among five stable knockdown 
clones generated, two clones showed at least 50% inhibition of Sec61β protein expression in 
Western blotting analysis (Fig. 20).  
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Figure 20. Sec61β knockdown efficiency in MDA-MB-231 cells.  The shRNA were 
stable transfected to MDA-MB-231 cells through retrovirus infection.  The transfectants 
were then selected with 1 μg/mL puromycin for 2 weeks to get stable clones. 
 
 
In this study, we showed both ligand- and H2O2-induced MET nuclear accumulation 
significantly decreased in Sec61β knockdown cells in compare to the knockdown control cells 
(Fig. 21).  The inhibition effect was further validated by confocal microscopy (Fig. 22).  
Together, these data provide evidence to show that MET travels through the ER for its nuclear 
translocation and it depends on Sec61 translocon complex to transport from ER into nucleus. 
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(A) 
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(B) 
 
 
 
 
Figure 21. Knock-down Sec61β diminishes MET nuclear translocation.  MDA-
MB-231 shSec61β stable clones were treated with A, H2O2 and B, HGF before fractionation, 
and isolated fractions were subjected to Western blot analysis with the indicated antibodies. 
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Figure 22. MET subcellular location in COPI and Sec61β knockdown MDA-MB-
231 cells.  Cells were treated with 100 ng/mL HGF for 2 h or H2O2 for 30 min and subjected 
to immunostaining with anti-MET and DAPI.   
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3.4 Membrane-bound MET trafficking through organelles 
This study has demonstrated that MET is retrograde transported from plasma membrane, 
Golgi apparatus and ER to nucleus.  The organelle membrane fraction were then examined 
to investigate if MET remains membrane-bound throughout the transportation process.  The 
organelle membrane were collected by using ProteoExtract®  Subcellular Proteome Extraction 
Kit and then analyzed by Western blotting.  According to the instructions provided with the 
kit, the cells were swelled and the proteins that are not membrane bounded were collected as 
cytosolic fraction, then the organelle membrane as well as membrane bounded proteins were 
collected in the organelle membrane fraction.  As shown in the figure, most of MET appears 
in the organelle fraction but not the cytosolic fraction after H2O2 treatment, indicating that 
MET remains membrane bounded during the transportation (Fig. 23).   
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Figure 23. MET locates in the organelle membrane fraction during nuclear 
transportation.  MDA-MB-231 cells were treated with 10 µM H2O2 for the time indicated 
and then harvested by using ProteoExtract®  Subcellular Proteome Extraction Kit following 
the instructions provided.  The protein extracts were analyzed through Western blotting.  
Tubulin were used to indicate the cytosol fractions, calnexin were used to indicate the 
organelle membrane, and Sp1 were used to indicate the nucleic fraction. 
 
 
Based on the data shown by Wang et al., RTKs follow the INTERNET mechanism will 
mainly detected in the organelle membrane fraction, while the RTKs which follow INFS 
transprtaion mechanism, for example, the FGFR-1, will be detected in the cytosolic fraction 
(Wang et al., 2012).  Thus, the data shown in Figure 23 can leads to the conclusion that MET 
nuclear transportation belongs to the INTERNET mechanism. 
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Chapter 4  
Conclusion and Discussion 
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To date, the function of nuclear MET is not well characterized as MET nuclear 
localization is not universally inducible by ligand (Gomes et al., 2008; Matteucci et al., 2009; 
Pozner-Moulis et al., 2006) and is not the main response to ligand stimulation. Furthermore, 
it is difficult to distinguish the function of nuclear MET from traditional RTK signaling 
cascade under ligand stimulation.  Here, we demonstrate that both ligand- and H2O2-induced 
MET nuclear translocation follows a previously reported membrane-bound vesicle transport 
mechanism.  However, we found that the level of MET nuclear translocation was 
significantly different between ligand treatment and stress stimulation.  
Built on the basis of the previously identified membrane-bound EGFR nuclear 
trafficking mechanism (Wang et al., 2012), we show that full-length MET also utilizes the 
INTERNET mechanism for tis intracellular transport, indicating that this trafficking 
mechanism is not restricted to the EGFR family, and suggesting MET may also have biological 
functions in nucleus that are similar to EGFR.  
The average HGF concentration in the serum of breast cancer patients has been reported 
to be about 0.5 ng/mL (Taniguchi et al., 1995), which suggests that MET nuclear translocation 
is not the primary response to HGF under physiological condition. Our results indicated that 
cellular stress initiates the nuclear translocation and non-canonical MET signaling more 
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potently than traditional ligand stimulation.  Moreover, doxorubicin treatment also induced 
the presence of MET in the nucleus, suggesting that MET nuclear translocation may function 
to overcome the stress, i.e. it may contribute to cell survival through manage replication stress 
or even involved in DNA repair and check point regulation.  Some researchers reported that 
inhibiting both MET and EGFR kinase activity can induce synergistic effect in cancer 
treatments including breast cancer treatment (Castoldi et al., 2013; Mueller et al., 2010; 
Takeuchi et al., 2012).  Further, it has been reported that acquired MET overexpression 
correlates to development of secondary EGFR TKI resistance in non-small-cell lung cancer 
(Cappuzzo et al., 2009; Engelman et al., 2007) and the overexpression of MET in breast cancer 
patients and the association of EGFR/MET contribute to EGFR TKI resistance in breast cancer 
(Mueller et al., 2010).  
In summary, the discovery of nuclear MET function may uncover a mechanism by MET 
overexpression promotes cell survival and drug resistance in cancer cells, while the 
understanding of transportation mechanism, which our study contributes, provides a potential 
mechanism to block nuclear transportation of MET. 
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